Satellos Bioscience Begins Phase 1B Trial for Duchenne Muscular Dystrophy

Toronto, Wednesday, 11 December 2024.
Satellos Bioscience has dosed the first participant in their Phase 1B trial of SAT-3247, marking a key step in developing treatments for Duchenne Muscular Dystrophy.